Clinical-stage biopharmaceutical company
Appears in 1 story
Developing LUT014 following positive Phase 2 results
Colorectal cancer patients on EGFR inhibitors often develop painful, cherry-red acneiform rashes. A third of them cut back or pause their cancer therapy because of it. Lutris Pharma's experimental gel reduced that non-adherence rate to 10.3%, down from 28.2% with placebo, in a 118-patient Phase 2 trial.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
